Zehra Betül Kingir et al.
Ulusal travma ve acil cerrahi dergisi = Turkish journal of trauma & emergency surgery : TJTES, 25(3), 213-221 (2019-05-29)
The aim of this study was to evaluate the possible protective effects of dapagliflozin in an experimental sepsis model in rats. Saline (1 mL/kg, p.o.) or dapagliflozin (10 mg/kg, p.o.) was administered to Sprague-Dawley rats for 5 days prior to...
Fengjuan Huang et al.
Frontiers in endocrinology, 10, 441-441 (2019-07-25)
Tubulointerstitial fibrosis (TIF) plays an important role in the progression of renal fibrosis in diabetic nephropathy (DN). Accumulating evidence supports a crucial inhibitory effect of dapagliflozin, a SGLT2 inhibitor, on TIF, but the underlying mechanisms remain largely unknown. This study...
Nannan Zhang et al.
Cardiovascular diabetology, 18(1), 107-107 (2019-08-21)
Heart failure with preserved ejection fraction (HFpEF) is a difficult disease with high morbidity and mortality rates and lacks an effective treatment. Here, we report the therapeutic effect of dapagliflozin, a sodium-glucose cotransporter 2 inhibitor (SGLT2i), on hypertension + hyperlipidemia-induced HFpEF in a...
Ryo Shibusawa et al.
Scientific reports, 9(1), 9887-9887 (2019-07-10)
The new type 2 diabetes drug, dapagliflozin, reduces blood glucose levels and body weight by inhibiting sodium glucose transporter 2 (SGLT2) in proximal tubular cells. SGLT2 inhibitors might modulate glucose influx into renal tubular cells, thereby regulating the metabolic conditions...
Dapagliflozin - a breakthrough in the search for drugs to treat HFrEF.
Nature reviews. Cardiology, 16(12), 700-700 (2019-10-04)